NCT04461353View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

August 17, 2020

Study Completion Date

August 17, 2020

Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
DRUG

Aerolized Hydroxychloroquine Sulfate

sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.

OTHER

Placebo

The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.

Trial Locations (1)

10065

The Rockefeller University, New York

All Listed Sponsors
collaborator

Rockefeller University

OTHER

lead

Pulmoquine Therapeutics, Inc

INDUSTRY

NCT04461353 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter